Ildong Pharmaceutical Group Pursues Partnering Opportunities for GLP-1 Obesity Treatment and Other Pipelines at BIO USA 2026

Ildong Pharmaceutical Group is participating in BIO USA 2026, where it will showcase its new drug pipelines and engage in business development activities, including partnering meetings with global pharmaceutical and biotechnology companies.

BIO USA is the world's largest biotechnology and pharmaceutical networking event, bringing together industry leaders for technology exchange and business collaboration. This year's conference will be held in San Diego, California, from June 22 to 25.

During the event, Ildong Pharmaceutical Group plans to explore collaboration opportunities related to drug development and commercialization, including research and development partnerships, licensing-out agreements, and open innovation initiatives with numerous international companies and global partners.

Ildong Pharmaceutical will hold partnering meetings focused on ID110521156, a GLP-1 receptor agonist (GLP-1 RA) being developed for obesity and diabetes treatment, as well as padoprazan, a potassium-competitive acid blocker (P-CAB) currently under development for the treatment of peptic ulcer-related diseases.

ID110521156 is an orally administered small-molecule synthetic drug candidate that offers several advantages over existing peptide-based injectable therapies, including differentiated pharmacological properties, manufacturing efficiency, cost-effectiveness, and patient convenience.

Notably, the compound maintains therapeutically effective blood concentrations for more than 18 hours without accumulation in the body, making it well suited for once-daily, long-term oral administration.

Previously, ID110521156 demonstrated body weight reduction of up to 13.8% over four weeks in a Phase 1 clinical trial. The candidate also exhibited a favorable safety profile, with no serious adverse events reported, including the gastrointestinal disorders and hepatotoxicity commonly associated with existing therapies.

Based on the Phase 1 clinical data, Ildong Pharmaceutical plans to continue discussions with existing and prospective global partners regarding commercialization opportunities, including potential licensing-out agreements.

Padoprazan, a P-CAB therapy, is being co-developed with Daewon Pharmaceutical. Daewon Pharmaceutical is currently conducting a Phase 3 clinical trial in Korea to evaluate the efficacy and safety of padoprazan in patients with erosive and non-erosive gastroesophageal reflux disease (GERD).

Leveraging its overseas rights to padoprazan, Ildong Pharmaceutical is pursuing licensing-out opportunities in international markets. The company is also considering follow-up strategies, including the launch of the product under its own brand upon completion of domestic development.

Idience, Ildong Pharmaceutical Group's oncology-focused R&D affiliate, will present its oncology pipeline, including:

• Venadaparib, a PARP inhibitor
• ID12241, a pan-KRAS inhibitor
• A dual-payload antibody-drug conjugate (ADC) platform

Venadaparib has received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA). The candidate is currently being evaluated in multiple clinical studies, including a Phase 2a combination therapy trial for gastric cancer in Korea and the United States.

Last year, Idience signed a licensing-out agreement valued at approximately KRW 70 billion covering the Eurasian Economic Union (EAEU) and Gulf Cooperation Council (GCC) regions.

An official from Ildong Pharmaceutical Group stated, “In addition to our pre-arranged partnering meetings for each affiliate and pipeline, we plan to actively engage in networking activities aimed at generating global business opportunities, including commercialization discussions related to our novel drug candidates.”